1221403-99-1

Basic information

• Product Name: 2'-O-methacryloylglycylphenylalanylleucylglycyl-docetaxel
• Synonyms: 2'-O-methacryloylglycylphenylalanylleucylglycyl-docetaxel
• CAS NO: 1221403-99-1
• Molecular Weight: 1250.41
• Mol File: 1221403-99-1.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 2'-O-methacryloylglycylphenylalanylleucylglycyl-docetaxel(CAS DataBase Reference)
• NIST Chemistry Reference: 2'-O-methacryloylglycylphenylalanylleucylglycyl-docetaxel(1221403-99-1)
• EPA Substance Registry System: 2'-O-methacryloylglycylphenylalanylleucylglycyl-docetaxel(1221403-99-1)

Safety Data

• Hazardous Substances Data: 1221403-99-1(Hazardous Substances Data)

Upstream product

• 104845-48-9 N-methacryloylglycylphenylalanylleucylglycine 
• 114915-20-7 Docetaxel 

Relevant articles and documents

Comparison of active and passive targeting of docetaxel for prostate cancer therapy by HPMA copolymer-RGDfK conjugates

N-(2-Hydroxypropyl)methacrylamide (HPMA) copolymer-docetaxel-RGDfK conjugate was synthesized, characterized, and evaluated in vitro and in vivo in comparison with untargeted low and high molecular weight HPMA copolymer-docetaxel conjugates. The targeted conjugate was designed to have a hydrodynamic diameter below renal threshold to allow elimination post treatment. All conjugates demonstrated the ability to inhibit the growth of DU145 and PC3 human prostate cancer cells and the HUVEC at low nanomolar concentrations. The targeted conjugate showed active binding to αvβ 3 integrins in both HUVEC and DU145 cells, whereas the untargeted conjugate demonstrated no evidence of specific binding. Efficacy at two concentrations (20 mg/kg and 40 mg/kg) was evaluated in nu/nu mice bearing DU145 tumor xenografts treated with a single dose of conjugates and compared with controls. RGDfK targeted and high molecular weight nontargeted conjugates exhibited the highest antitumor efficacy as evaluated by tumor regression. These results demonstrate that αvβ3 integrin targeted polymeric conjugates with improved water solubility, reduced toxicity and ease of elimination post treatment in vivo are promising candidates for prostate cancer therapy.

RADIATION ENHANCED MACROMOLECULAR DELIVERY OF THERAPEUTIC AGENTS FOR CHEMOTHERAPY

Described herein are anti-cancer compounds composed of a macromolecule comprising (1) at least one anti-cancer agent directly or indirectly bonded to the macromolecule and (2) at least one high Z element directly or indirectly bonded to the macromolecule